VG Life Sciences Inc. VGLS OTC

VG Life Sciences Inc. (VGLS) reported total assets of $0.00 and total liabilities of $4.62M for fiscal year 2022, resulting in total equity of $-4.62M.

The company held $0.00 in cash and short-term investments. Total debt stood at $2.18M, with net debt of $2.18M. The Debt-to-Equity (D/E) ratio was -0.47 (conservative).

Current ratio is 0, which may signal tight short-term liquidity. Interest coverage is -15.4x (weak).

Criteria supported by this page:

• HEALTH (0/100, Fail) — the balance sheet shows elevated risk in debt or liquidity metrics
• MOAT (28/100) — Total assets $0.00 and equity $-4.62M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity -0.47 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 52/100 with 2/7 criteria passed.

SBMFF

Sino Biopharmaceutical Limited

$0.76

-8.60%

PHGUF

Pharming Group N.V.

$1.75

+15.89%

DOMH

Dominari Holdings Inc.

$3.09

+3.00%

MMIRF

MedMira Inc.

$0.05

+0.00%

ZIVO

ZIVO Bioscience, Inc.

$2.12

-3.64%

KNBIF

Kane Biotech Inc.

$0.02

-3.64%

SILO

Silo Pharma, Inc.

$0.40

-7.17%

OCTHF

Oxford Cannabinoid Technologies Holdings Plc

$0.00

+0.00%